BPC June 16 update

Acorda ACOR Inbrija launched in Germany; AC Immune ACIU RHHBY Disappointing Alzheimer's results

Pre-Market Updates

Yesterday's BIOrdle ticker was TRVN. Trevena, Inc. (NASDAQ: TRVN) is a biopharmaceutical company developing treatments for central nervous system (CNS) disorders. Trevena has an approved drug, OLINVYK to treat acute pain. Shares closed yesterday up 4% at $0.41.

__________________________

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Esteve Pharmaceuticals GmbH has launched INBRIJA to treat episodic motor fluctuations in adult patients with Parkinson's disease in Germany.

AC Immune SA (NASDAQ: ACIU) and the Roche Group (OTCQX: RHHBY) announced results from their Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial of crenezumab. Data reported that crenezumab did not statistically significantly slow or prevent cognitive decline.

Heart Test Laboratories, Inc. (NASDAQ: HSCS) commenced trading yesterday after it completed its initial public offering of 1,500,000 units of common stock and a warrant at $4.25 per unit.

Arcellx, Inc. (NASDAQ: ACLX) priced its follow-on offering of 7,000,000 shares at $16.00 per share. The gross proceeds are expected to be $112 million.

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) announced interim efficacy results from its Phase 1 trial of cosibelimab to treat cutaneous squamous cell carcinoma (cSCC). The objective response rate (ORR) determined by independent central review (ICR) was 54.8%.

Kintara Therapeutics, Inc. (NASDAQ: KTRA) shares pulled back after yesterday's jump off of the FDA granting Fast Track Designation to VAL-083.

Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced topline results from Part 3 of the Phase 1 EPIPHAST study for its AQST-109 epinephrine oral film. The median time to maximum concentration (Tmax) was observed to be 12 minutes for AQST-109 compared to 50 minutes for the epinephrine 0.3mg intra-muscular (IM) injection from Part 2 of the EPIPHAST study.

Pre-Market Advancers

CompanyPriceChange
TALS
Talaris Therapeutics Inc.
$1.01 +1.01  +100%
AKUS
Akouos Inc.
$1.01 +1.01  +100%
QNRX
Quoin Pharmaceuticals Ltd.
$1.01 +1.01  +100%
BBI
Brickell Biotech, Inc.
$1.01 +1.01  +100%
AKBA
Akebia Therapeutics Inc.
$1.01 +1.01  +100%
ALNA
Allena Pharmaceuticals Inc.
$1.01 +1.01  +100%
PRVB
Provention Bio Inc.
$1.01 +1.01  +100%
IVC
Invacare Corporation
$1.01 +1.01  +100%
ENSC
Ensysce Biosciences Inc.
$1.01 +1.01  +100%
BNTC
Benitec Biopharma Inc.
$1.01 +1.01  +100%

Pre-Market Decliners

CompanyPriceChange
CADL
Candel Therapeutics Inc.
$1.01 -1.01  -100%
CLVS
Clovis Oncology Inc.
$1.01 -1.01  -100%
ENDP
Endo International plc
$1.01 -1.01  -100%
TYRA
Tyra Biosciences Inc.
$1.01 -1.01  -100%
CTKB
Cytek Biosciences Inc.
$1.01 -1.01  -100%
BLTE
Belite Bio Inc
$1.01 -1.01  -100%
MREO
Mereo BioPharma Group plc
$1.01 -1.01  -100%
CRTX
Cortexyme Inc.
$1.01 -1.01  -100%
PULM
Pulmatrix Inc.
$1.01 -1.01  -100%
RXST
RxSight Inc.
$1.01 -1.01  -100%